Kymera Therapeutics Inc (NASDAQ: KYMR) Could Have Exceptional Returns?

In the last trading session, 1.35 million shares of the Kymera Therapeutics Inc (NASDAQ:KYMR) were traded, and its beta was 2.19. Most recently the company’s share price was $28.57, and it changed around -$5.01 or -14.92% from the last close, which brings the market valuation of the company to $1.86B. KYMR currently trades at a discount to its 52-week high of $53.27, offering almost -86.45% off that amount. The share price’s 52-week low was $19.44, which indicates that the current value has risen by an impressive 31.96% since then.

Kymera Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.22. If we narrow it down even further, the data shows that 0 out of 19 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended KYMR as a Hold, whereas 13 deemed it a Buy, and 0 rated it as Underweight.

Kymera Therapeutics Inc (NASDAQ:KYMR) trade information

Instantly KYMR has showed a red trend with a performance of -14.92% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 35.98 on recent trading dayincreased the stock’s daily price by 20.59%. The company’s shares are currently down -28.98% year-to-date, but still down -15.20% over the last five days. On the other hand, Kymera Therapeutics Inc (NASDAQ:KYMR) is 29.45% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $55, which translates to bulls needing to increase their stock price by 48.05% from its current value. Analyst projections state that KYMR is forecast to be at a low of $54 and a high of $57.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -26.36%. Kymera Therapeutics Inc earnings are expected to increase by -23.88% in 2025, but the outlook is negative -10.63% per year for the next five years.

KYMR Dividends

Kymera Therapeutics Inc’s next quarterly earnings report is expected to be released in June.

BAKER BROS. ADVISORS LP, with 8.2069% or 6.0 million shares worth $178.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

T. Rowe Price New Horizons Fund, Inc. and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.09 shares worth $88.4 million, making up 4.75% of all outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held roughly 2.35 shares worth around $67.18 million, which represents about 3.61% of the total shares outstanding.